3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
6
Endocrine
6
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
69
Osteosarcoma
29
Sarcoma, Ewing
20
Rhabdomyosarcoma
17
Ovarian Neoplasms
17
Melanoma
17
Neuroblastoma
15
Gastrointestinal Stromal Tumors
15
Colorectal Neoplasms
12
Bone Neoplasms
12
Wilms Tumor
11
Sarcoma, Kaposi
11
Rhabdoid Tumor
11
Neoplasms
11
Lymphoma, Non-Hodgkin
10
Hepatoblastoma
10
Glioma
10
Breast Neoplasms
10
Stomach Neoplasms
9
Medulloblastoma
9
Liposarcoma
9
Ependymoma
9
Neurofibrosarcoma
8
Neuroectodermal Tumors, Primitive, Peripheral
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Hepatocellular
8
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Cancer, Papillary
×
Sarcoma
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA